These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity. Erol MK; Coban DT; Sari ES; Bilgin AB; Dogan B; Ozdemir O; Tunay ZO Arq Bras Oftalmol; 2015; 78(6):340-3. PubMed ID: 26677033 [TBL] [Abstract][Full Text] [Related]
30. OUTCOMES AFTER LASER VERSUS COMBINED LASER AND BEVACIZUMAB TREATMENT FOR TYPE 1 RETINOPATHY OF PREMATURITY IN ZONE I. Yoon JM; Shin DH; Kim SJ; Ham DI; Kang SW; Chang YS; Park WS Retina; 2017 Jan; 37(1):88-96. PubMed ID: 27347645 [TBL] [Abstract][Full Text] [Related]
31. [The clinical study on intravitreous injection of ranibizumab for aggressive posterior retinopathy of prematurity]. Tian R; Zhang G; Tang S; Guo J; Tan W Zhonghua Yan Ke Za Zhi; 2015 Nov; 51(11):822-5. PubMed ID: 26850583 [TBL] [Abstract][Full Text] [Related]
32. Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity. Hoppe C; Holt DG; Arnold BF; Thinda S; Padmanabhan SP; Oatts JT J AAPOS; 2022 Dec; 26(6):305.e1-305.e6. PubMed ID: 36265750 [TBL] [Abstract][Full Text] [Related]
33. Short-term retinal detachment risk after treatment of type 1 retinopathy of prematurity with laser photocoagulation versus intravitreal bevacizumab. Barry GP; Tauber KA; Fisher M; Greenberg S; Zobal-Ratner J; Binenbaum G J AAPOS; 2019 Oct; 23(5):260.e1-260.e4. PubMed ID: 31513902 [TBL] [Abstract][Full Text] [Related]
34. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity. Sukgen EA; Koçluk Y Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):49-55. PubMed ID: 30397793 [TBL] [Abstract][Full Text] [Related]
35. Effects of Intravitreal Ranibizumab in the Treatment of Retinopathy of Prematurity in Chinese Infants. Yi Z; Su Y; Zhou Y; Zheng H; Ye M; Xu Y; Chen C Curr Eye Res; 2016 Aug; 41(8):1092-1097. PubMed ID: 26580816 [TBL] [Abstract][Full Text] [Related]
36. COMPARISON OF INTRAVITREAL INJECTION OF RANIBIZUMAB VERSUS LASER THERAPY FOR ZONE II TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY. Zhang G; Yang M; Zeng J; Vakros G; Su K; Chen M; Li H; Tian R; Li N; Tang S; He H; Tan W; Song X; Zhuang R; Retina; 2017 Apr; 37(4):710-717. PubMed ID: 27529839 [TBL] [Abstract][Full Text] [Related]
37. Ranibizumab after laser photocoagulation failure in retinopathy of prematurity (ROP) treatment. Gotz-Więckowska A; Chmielarz-Czarnocińska A; Pawlak M; Gadzinowski J; Mazela J Sci Rep; 2017 Sep; 7(1):11894. PubMed ID: 28928468 [TBL] [Abstract][Full Text] [Related]
38. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Castellanos MA; Schwartz S; García-Aguirre G; Quiroz-Mercado H Br J Ophthalmol; 2013 Jul; 97(7):816-9. PubMed ID: 23221964 [TBL] [Abstract][Full Text] [Related]
39. Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy. Chan JJT; Lam CPS; Kwok MKM; Wong RLM; Lee GKY; Lau WWY; Yam JCS Sci Rep; 2016 Jun; 6():27082. PubMed ID: 27256987 [TBL] [Abstract][Full Text] [Related]
40. Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review. Tsiropoulos GN; Seliniotaki AK; Haidich AB; Ziakas N; Mataftsi A Int Ophthalmol; 2023 Mar; 43(3):1027-1062. PubMed ID: 36214992 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]